Objective: To probe into combined application value of Qili Qiangxin capsules combined with trimetazidine treatment on heart failure patients with ischemic cardiomyopathy. Method: From January 2013 to December 2013

110 heart failure patients with ischemic cardiomyopathy were selected in our hospital. The patients were divided into study group and control group randomly. The patients in control group were treated with trimetazidine as clinical medication. The patients in study group were treated with trimetazidine combined Qili Qiangxin capsules drug treatment. The clinical treatment of the patients in two groups were compared and analyzed. Result: Compared with control group

the patients in study group after treatment

New York Heart Association(NYHA) class for the ratios of gradeⅠ and gradeⅡ were increased significantly

up to 21.82% and 67.27%

the ratios of grade Ⅲ and grade Ⅳ were decreased significantly

only 10.91% and 1.82%

the difference were significant statistically(P<0.05). Compared with control group

the patients in study group the ratio of effective was 58.18% and the total efficiency was 92.73%

there were improved significantly

while the ratio of inefficient was 7.27%

there was decreased significantly

the difference were significant statistically(P<0.05).Compared with control group

the patients in study group after treatment

the left ventricular end-diastolic volume(LVEDV) was (87.53±12.40) mL

left ventricular end-systolic volume (LVESV)was (67.01±13.12) mL

left ventricular end-diastolic diameter (LVEDD) was (18.32±2.78) mm

left ventricular end systolic pressure(LV ESP)was (33.54±5.16) mm

there were decreased significantly

the level of left ventricular ejection fraction (LVEF) was (53.86±7.15)%

there was increased significantly

the difference were significant statistically(P<0.05). Compared with control group

the patients in study group after treatment the levels of N-terminal pro-B-type natricuretic prptide(NT-proBNP) was (417.13±90.42) ng·L-1

cordiac tioponin Ⅰ(cTnI) was (0.30±0.10) μg·L-1

hypersensitive C-reactive protein(hs-CRP) was (8.97±3.85) mg·L-1

there were reduced significantly

the difference were significant statistically(P<0.05). Conclusion: Qili Qiangxin capsules combined with trimetazidine have a positive role in promoting for reversal and improvement of cardiac function

left ventricular remodeling and neuroendocrine factors in heart failure patients with ischemic cardiomyopathy. It was suitable for clinical application and promotion.